CLR 1404 I-131

Drug Profile

CLR 1404 I-131

Alternative Names: (131)I-CLR1404; 18-(p-[I-131]-iodophenyl)octadecyl phosphocholine; 131I-CLR1404; 131I-NM 404; CLR 131; CLR1404 I-131; HOT; I-131-CLR1404; NM404

Latest Information Update: 05 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Michigan Medical School
  • Developer Cellectar Biosciences; University of Wisconsin-Madison
  • Class Antineoplastics; Phospholipids; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haematological malignancies; Multiple myeloma
  • Phase I/II Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 18 May 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the 2017 Annual meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 27 Apr 2017 Pharmacodynamics data from a preclinical study in Solid tumours released by Cellectar Biosciences
  • 18 Apr 2017 Cellectar Biosciences has patent protection for method of use for CLR 1404 I-131 and CLR 125 in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top